Journal of Genetic Medicine

  • 제12권2호
  • /
  • Pages.100-108
  • /
  • 2015
  • /
  • 1226-1769(pISSN)
  • /
  • 2383-8442(eISSN)
대한의학유전학회 (Korean Society of Medical Genetics and Genomics)
권호 표지
DOI QR코드

DOI QR Code

Noninvasive fetal RHD genotyping using cell-free fetal DNA incorporating fetal RASSF1A marker in RhD-negative pregnant women in Korea

  • Han, Sung-Hee (Division of Prenatal Molecular Genetics, Department of Laboratory Medicine, Seoul Clinical Laboratories) ;
  • Yang, Young-Ho (Division of Prenatal Molecular Genetics, Department of Laboratory Medicine, Seoul Clinical Laboratories) ;
  • Ryu, Jae-Song (Division of Prenatal Molecular Genetics, Department of Laboratory Medicine, Seoul Clinical Laboratories) ;
  • Kim, Young-Jin (Division of Prenatal Molecular Genetics, Department of Laboratory Medicine, Seoul Clinical Laboratories) ;
  • Lee, Kyoung-Ryul (Division of Prenatal Molecular Genetics, Department of Laboratory Medicine, Seoul Clinical Laboratories)
  • 투고 : 2015.10.12
  • 심사 : 2015.11.20
  • 발행 : 2015.12.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Purpose: Conventional methods for the prenatal detection of fetal RhD status involve invasive procedures such as fetal blood sampling and amniocentesis. The identification of cell-free fetal DNA (cffDNA) in maternal plasma creates the possibility of determining fetal RhD status by analyzing maternal plasma DNA. However, some technical problems still exist, especially the lack of a positive control marker for the presence of fetal DNA. Therefore, we assessed the feasibility and accuracy of fetal RHD genotyping incorporating the RASSF1A epigenetic fetal DNA marker from cffDNA in the maternal plasma of RhD-negative pregnant women in Korea. Materials and Methods: We analyzed maternal plasma from 41 pregnant women identified as RhD-negative by serological testing. Multiplex real-time PCR was performed by amplifying RHD exons 5 and 7 and the SRY gene, with RASSF1A being used as a gender-independent fetal epigenetic marker. The results were compared with those obtained by postnatal serological analysis of cord blood and gender identification. Results: Among the 41 fetuses, 37 were RhD-positive and 4 were RhD-negative according to the serological analysis of cord blood. There was 100% concordance between fetal RHD genotyping and serological cord blood results. Detection of the RASSF1A gene verified the presence of cffDNA, and the fetal SRY status was correctly detected in all 41 cases. Conclusion: Noninvasive fetal RHD genotyping with cffDNA incorporating RASSF1A is a feasible, reliable, and accurate method of determining fetal RhD status. It is an alternative to amniocentesis for the management of RhD-negative women and reduces the need for unnecessary RhIG prophylaxis.

키워드

참고문헌

  1. Portmann C, Ludlow J, Joyce A, Chan FY. Antecedents to and outcomes of Rh(D) immunization: mater mothers hospital, Brisbane, 1988-1995. Aust N Z J Obstet Gynaecol 1997;37:12-6. https://doi.org/10.1111/j.1479-828X.1997.tb02210.x
  2. Moise KJ Jr. Management of rhesus alloimmunization in pregnancy. Obstet Gynecol 2002;100:600-11.
  3. Lo YM, Corbetta N, Chamberlain PF, Rai V, Sargent IL, Redman CW, et al. Presence of fetal DNA in maternal plasma and serum. Lancet 1997;350:485-7. https://doi.org/10.1016/S0140-6736(97)02174-0
  4. Lo YM, Hjelm NM, Fidler C, Sargent IL, Murphy MF, Chamberlain PF, et al. Prenatal diagnosis of fetal RhD status by molecular analysis of maternal plasma. N Engl J Med 1998;339:1734-8. https://doi.org/10.1056/NEJM199812103392402
  5. Daniels G, Finning K, Martin P, Massey E. Noninvasive prenatal diagnosis of fetal blood group phenotypes: current practice and future prospects. Prenat Diagn 2009;29:101-7. https://doi.org/10.1002/pd.2172
  6. Wikman AT, Tiblad E, Karlsson A, Olsson ML, Westgren M, Reilly M. Noninvasive single-exon fetal RHD determination in a routine screening program in early pregnancy. Obstet Gynecol 2012;120:227-34. https://doi.org/10.1097/AOG.0b013e31825d33d9
  7. Tynan JA, Angkachatchai V, Ehrich M, Paladino T, van den Boom D, Oeth P. Multiplexed analysis of circulating cell-free fetal nucleic acids for noninvasive prenatal diagnostic RHD testing. Am J Obstet Gynecol 2011;204:251.e1-6. https://doi.org/10.1016/j.ajog.2010.09.028
  8. Bombard AT, Akolekar R, Farkas DH, VanAgtmael AL, Aquino F, Oeth P, et al. Fetal RHD genotype detection from circulating cell-free fetal DNA in maternal plasma in non-sensitized RhD negative women. Prenat Diagn 2011;31:802-8. https://doi.org/10.1002/pd.2770
  9. Chim SS, Tong YK, Chiu RW, Lau TK, Leung TN, Chan LY, et al. Detection of the placental epigenetic signature of the maspin gene in maternal plasma. Proc Natl Acad Sci U S A 2005;102:14753-8. https://doi.org/10.1073/pnas.0503335102
  10. Chan KC, Ding C, Gerovassili A, Yeung SW, Chiu RW, Leung TN, et al. Hypermethylated RASSF1A in maternal plasma: A universal fetal DNA marker that improves the reliability of noninvasive prenatal diagnosis. Clin Chem 2006;52:2211-8. https://doi.org/10.1373/clinchem.2006.074997
  11. Pertl B, Sekizawa A, Samura O, Orescovic I, Rahaim PT, Bianchi DW. Detection of male and female fetal DNA in maternal plasma by multiplex fluorescent polymerase chain reaction amplification of short tandem repeats. Hum Genet 2000;106:45-9. https://doi.org/10.1007/s004390051008
  12. Page-Christiaens GC, Bossers B, van der Schoot CE, de Haas M. Use of bi-allelic insertion/deletion polymorphisms as a positive control for fetal genotyping in maternal blood: first clinical experience. Ann N Y Acad Sci 2006;1075:123-9. https://doi.org/10.1196/annals.1368.016
  13. Grunau C, Clark SJ, Rosenthal A. Bisulfite genomic sequencing: systematic investigation of critical experimental parameters. Nucleic Acids Res 2001;29:E65-5. https://doi.org/10.1093/nar/29.13.e65
  14. Legler TJ, Liu Z, Mavrou A, Finning K, Hromadnikova I, Galbiati S, et al. Workshop report on the extraction of foetal DNA from maternal plasma. Prenat Diagn 2007;27:824-9. https://doi.org/10.1002/pd.1783
  15. Chilcott J, Lloyd Jones M, Wight J, Forman K, Wray J, Beverley C, et al. A review of the clinical effectiveness and cost-effectiveness of routine anti-D prophylaxis for pregnant women who are rhesusnegative. Health Technol Assess 2003;7:iii-62.
  16. Finning KM, Martin PG, Soothill PW, Avent ND. Prediction of fetal D status from maternal plasma: introduction of a new noninvasive fetal RHD genotyping service. Transfusion 2002;42:1079-85. https://doi.org/10.1046/j.1537-2995.2002.00165.x
  17. van der Schoot CE, Hahn S, Chitty LS. Non-invasive prenatal diagnosis and determination of fetal Rh status. Semin Fetal Neonatal Med 2008;13:63-8. https://doi.org/10.1016/j.siny.2007.12.012
  18. Geifman-Holtzman O, Grotegut CA, Gaughan JP. Diagnostic accuracy of noninvasive fetal Rh genotyping from maternal blood--a metaanalysis. Am J Obstet Gynecol 2006;195:1163-73. https://doi.org/10.1016/j.ajog.2006.07.033
  19. Hahn S, Chitty LS. Noninvasive prenatal diagnosis: current practice and future perspectives. Curr Opin Obstet Gynecol 2008;20:146-51. https://doi.org/10.1097/GCO.0b013e3282f73349
  20. Yang YH, Han SH, Lee KR. Noninvasive prenatal diagnosis using cellfree fetal dna in maternal plasma: clinical applications. J Genet Med 2011;8:1-16. https://doi.org/10.5734/JGM.2011.8.1.1
  21. Wagner FF, Frohmajer A, Flegel WA. RHD positive haplotypes in D negative Europeans. BMC Genet 2001;2:10.
  22. Grootkerk-Tax MG, Soussan AA, de Haas M, Maaskant-van Wijk PA, van der Schoot CE. Evaluation of prenatal RHD typing strategies on cell-free fetal DNA from maternal plasma. Transfusion 2006;46:2142-8. https://doi.org/10.1111/j.1537-2995.2006.01044.x
  23. Zejskova L, Jancuskova T, Kotlabova K, Doucha J, Hromadnikova I. Feasibility of fetal-derived hypermethylated RASSF1A sequence quantification in maternal plasma--next step toward reliable noninvasive prenatal diagnostics. Exp Mol Pathol 2010;89:241-7. https://doi.org/10.1016/j.yexmp.2010.09.002
  24. Zhao F, Wang J, Liu R, Yang J, Cui K, Wu Y, et al. Quantification and application of the placental epigenetic signature of the RASSF1A gene in maternal plasma. Prenat Diagn 2010;30:778-82. https://doi.org/10.1002/pd.2546
  25. Papantoniou N, Bagiokos V, Agiannitopoulos K, Kolialexi A, Destouni A, Tounta G, et al. RASSF1A in maternal plasma as a molecular marker of preeclampsia. Prenat Diagn 2013;33:682-7. https://doi.org/10.1002/pd.4093
  26. Wagner FF, Flegel WA. RHD gene deletion occurred in the Rhesus box. Blood 2000;95:3662-8.
  27. Hwang YS. Haplotype frequencies of RH gene loci in Koreans. Korean J Blood Transfus 1996;7:233-40.
  28. Wang XD, Wang BL, Ye SL, Liao YQ, Wang LF, He ZM. Non-invasive foetal RHD genotyping via real-time PCR of foetal DNA from Chinese RhD-negative maternal plasma. Eur J Clin Invest 2009;39:607-17. https://doi.org/10.1111/j.1365-2362.2009.02148.x
  29. Kim JY, Kim SY, Kim CA, Yon GS, Park SS. Molecular characterization of D- Korean persons: development of a diagnostic strategy. Transfusion 2005;45:345-52. https://doi.org/10.1111/j.1537-2995.2005.04311.x
  30. Luettringhaus TA, Cho D, Ryang DW, Flegel WA. An easy RHD genotyping strategy for D- East Asian persons applied to Korean blood donors. Transfusion 2006;46:2128-37. https://doi.org/10.1111/j.1537-2995.2006.01042.x